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To study the mechanisms of the development of hormone refractory prostate cancer, we established an androgen-independent (AI)
prostate cancer cell line derived from hormone-dependent (AD) LNCaP cells. Our previous studies have demonstrated that AI cells
are deficient in expression of p21
WAFl/CIP1 (p21) due to overexpressed AR and are resistant to apoptosis. In this study, the induction
of p53 and p21 expression by vinorelbine (Navelbine) was compared between AD and AI cells in an attempt to understand the
difference(s) in apoptotic signalling pathways in these cells. Using a series of deletion of p21 reporter constructs, we found that
vinorelbine mediated p21 induction in a p53-dependent manner in AD cells. In contrast, p21 expression restored by vinorelbine in AI
cells was found to be through both p53-dependent and-independent pathways. In the absence of two p53 binding sites, Spl-3 and
Spl-4 sites, in the promoter of human p21 gene, were found to be required for vinorelbine-mediated p21 activation. No p21
induction was observed by paclitaxel in AI cells. Exposure of AI cells to paciltaxel followed by vinorelbine produced synergism. Our
data, thus, provide a basis for the synergistic combination of vinorelbine and paclitaxel for the treatment of advanced prostate cancer.
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Vinorelbine is a third-generation vinca alkaloid that plays an
important role in the treatment of several human cancers,
including breast carcinoma, cancers of ovarian, prostate, and lung
as well as haematological malignancies (Budman, 1997; Trimble,
2000; Lilenbaum, 2001). In contrast to paclitaxel, vinorelbine binds
microtubules and prevents their polymerisation, thus interfering
with mitosis (Krikorian and Breillout, 1991). Previous studies have
demonstrated that independent of the type of effect by the
antimicrotubule agent on microtubule assembly (polymerisation
or depolymerisation), these drugs exhibit the ability to promote
apoptosis in cancer cells (Wang et al, 1999b, 2000, 2001; Budman
et al, 2000; Charles et al, 2001; Fan et al, 2001; Liu et al, 2001). One
of mechanisms of vinorelbine-induced apoptosis is thought to be
the upregulation of p21 and p53. Expression of p21 is regulated
through p53-dependent and -independent pathways (Blagosklonny
et al, 1995; Barboule et al, 1997; Torres and Horwitz, 1998; Wang
et al, 1999b).
Since the observations by Huggins and Hodges (1941) in the
early 1940s on the benefit of androgen ablation, no major
therapeutic advances have been achieved for prostate cancer
patients exhibiting hormone independence, disease metastatic to
regional lymph nodes or those with more distant metastases. The
majority of patients succumb to the growth of androgen-
independent disease within 6–18 months. To understand the
mechanisms of development of hormone refractory prostate
cancer, we established an androgen-independent (AI) prostate
cancer cell line derived from the hormone-dependent (AD) LNCaP
cells that lack p2l
WAF1/CIP1 (p21) expression and are resistant to the
induction of apoptosis (Gao et al, 1999). Our recent studies
demonstrate that silencing of p21 in AI cells is linked to the
overexpression of the AR in this cell line (Wang et al, 2001). In the
present study, we explore whether the microtubule targeting
agents, vinorelbine and paclitaxel, could induce p21 expression in
AI cells. We demonstrate that vinorelbine, but not paciltaxel, is
able to restore p21 expression of AI cells through both p53-
dependent and -independent pathways.
MATERIALS AND METHODS
Reagents
Monoclonal antibodies against p21, p53 and b-actin, as well
as secondary antibodies were purchased from DAKO Corporation
(Carpinteria, CA, USA) and Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA), respectively. Western blotting detection
reagents and ECL films were purchased from Amersham
Pharmacia Biotech Inc. (Buckinghamshire, England). Effectene
transfection reagent, and luciferase assay kit, pSV-b-galactosidase
control plasmid and its assay kit were obtained from Qiagen
(Valencia, CA, USA) and Promega (Madison, WI, USA), respec-
tively. Vinorelbine was provided by Glaxo SmithKline Inc.
(Research Triangle Park, NC, USA). Trichostatin A (TSA), taxol
(paclitaxel) and other chemicals were purchased from Sigma-
Aldrich (St Louis, MO, USA). Received 22 April 2003; revised 2 July 2003; accepted 31 July 2003
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sp21 constructs
The full p21-promoter luciferase reporter construct was a gift from
Dr Lewis Silverman (Mount Sinai School of Medicine, New York,
USA), and p21 reporters pWPdel-BstX I, pWPlOl, pWPdel-Sma I,
Spl-luc and mtSpl-luc were kindly provided by Dr Yoshihiro Sowa
(University of Medicine, Kamigyo-ku, Kyoto 602, Japan). The full-
length promoter is a 2.4-kb genomic fragment subcloned into the
HindIII site of the luciferase reporter vector, pGL2-basic (Promega,
Madison, WI, USA) (Datto et al, 1995). The pWPdel-BstX I( 133
to þ1 relative to the start site) contains all six Sp-1 sites without
the p53 binding site (Nakano et al, 1997; Sowa et al, 1997). The
pWPlOl, by deleting Spl-1 and Spl-2 from pWPdel -BstXI, consists
of a minimal promoter region of 101 relative to the transcriptional
start site containing four Spl binding sites, termed Spl-3, Spl-4 Spl-
5, and Spl-6. pWP-del-SmaI was generated by further deletion of
Spl-3 and Spl-4 from pWPlOl, which contains only two Spl sites,
Spl-5 and Spl-6. The Spl-luc and mtSpl-luc were reporters of
luciferase promoted by three tandems of repeats of consensus Spl
sites and mutant Spl sites.
Cell culture
LNCaP cells were purchased from the American Type Culture
Collection (Rockville, MD, USA) and maintained in RPMI-1640
(GIBCO, Gaithersburg, MD, USA) containing 10% heat-inactivated
bovine serum (FBS). The AI LNCaP subline derived from LNCaP
cells was maintained in RPMI-1640 medium containing 10%
charcoal-stripped, heat-inactivated FBS (CSFBS) (Hyclone Labora-
tories, Inc., Logan, UT, USA) and 5mgml
 1 of insulin as described
previously (Gao et al, 1999).
Western blotting of cellular protein extraction
Total cellular proteins were extracted from AD or AI cells under
the various treatment conditions as indicated, and Western
blotting assay was performed as described previously (Wang
et al, 1999a). Briefly, 50 or 100mg cellular extracts were separated
by 4/10% stack SDS–PAGE, electro-transferred to nitrocellulose
filters, and immunoblotted with monoclonal antibodies against
p53 and p21 or b-actin, respectively. Quantitation by densitometry
of the ECL films was performed using an Imaging Densitometer
Model GS-720 (Bio-Rad Lab. Hercules, CA, USA) and normalised
to the level of b-actin.
DNA transfection and luciferase activity assay
DNA transfection and luciferase activity assays were performed as
described previously with modifications (Wang et al, 1999a).
Androgen-dependent and AI cells in exponential growth in regular
serum medium in 60-mm dishes were washed once with serum-
free mammary epithelium growth medium (MEGM) and reincu-
bated in the MEGM. The cells were then transfected with 1mg
cDNA of p21-luciferase reporter and 0.5mgo fb-galactosidase
control vector DNA using Effectene according to the manufac-
turer’s instructions. At 1 day after the transfection, the cells were
exposed for an additional 24h to various concentrations of
vinorelbine or paclitaxel as indicated. The cells were washed,
lysed, and the lysis simultaneously assayed for activities of
luciferase and of b-galactosidase using the Promega assay systems
according to the manufacturer’s instructions. The luciferase
activity, normalised to galactosidase, was expressed as units per
milligram of protein.
Combination analysis
Exponentially growing LNCaP cells were planted in 96-well dishes
at a density of 5000 cells per well. At 24h after the incubation, the
cells were exposed to series dilution of paclitaxel, vinorelbine for 7
days or sequentially exposed to paclitaxel for 3 days, followed by
paclitaxel plus vinorelbine for an additional 4 days at maximal
concentration of 50nM, respectively. After the incubation, the cell
growth was measured by MTT as described previously (Kreis et al,
1997), and the percentages of inhibition (1-T/C%) were calculated,
and the data were analysed by a PC program, CalcuSyn, of Biosoft
edited by T-C Chou, Memorial Sloan-Kettering Cancer Center,
New York, and MP Hayball, at Cambridge, UK, 1996 (Wang et al,
1997), and Sigma Plot. Regression and statistical analysis were
performed using Sigma Plot program. Combination indexes (CI)
calculated by CalcuSyn were used to evaluate the outcomes of the
combination. Outcomes of the combinations were determined by
CI. If CI 41, the combination is antagonistic, CI¼1, additive and
CI o1, synergistic.
RESULTS
Kinetics of AD and Al cell growth
To study the mechanisms of the progression of hormone refractory
prostate cancer, we established an AI prostate cancer cell line
derived from AD LNCaP cells and demonstrated that Al cells are
resistant to apoptosis and are deficient in expression of p21, which
at least in part is due to the overexpressed AR (Gao et al, 1999;
Wang et al, 2001). Typical kinetic growth curves, as measured by
MTT, of those two cell lines in the presence or absence of androgen
are shown in Figure 1. No significant difference in growth rate
between AD and AI cells was observed when both cell lines were
incubated in the RPMI-1640 containing androgens (10% FBS;
Figure 1, left panel). However, growth of AD cells became much
slower as compared with their successors when the cells were
grown in the same medium containing no androgens (10% CSFBS;
Figure 1, right panel), confirming that androgens are required for
the growth of the androgen-dependent cells. A similar growth rate
was obtained when AI cell were fed with full serum medium as
compared with the coal-stripped serum, demonstrating that the
cells become AI (Figure 1, left and right panels).
Induction of p53 and p21
WAFI/C1P1 expression by
vinorelbine in AD and AI cells
Induction of p53 and p21 by antimicrotubule agents has been
considered to be one mechanism involved in the apoptotic process
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Figure 1 Typical kinetic curves of AD and AI cell growth in the presence
or absence of androgens. AD and AI cells grown exponentially were
harvested and reincubated in 96-well dish at a density of 2500 cells per well
in 200ml of RPMI-1640 medium containing 10% FBS (panel A) or 10%
CSFBS (panel B). The cells were maintained in 5% CO2 incubator at 371C
for different periods of time as indicated. The growth of cells was then
measured by MTT as described in the ‘Materials and Methods’.
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sin cancer cells (Blagosklonny et al, 1995; Barboule et al, 1997;
Torres and Horwitz, 1998; Wang et al, 1999b). To explore whether
vinorelbine and paclitaxel are able to induce p21 expression in AD
and AI cells that are deficient in p21, and the possible differences
between AD and AI cells in expression of p53 and p21 in response
to treatments with vinorelbine or paclitaxel, the resultant levels of
p53 and p21 were determined by Western blotting. As shown in
Figures 2 and 3, exposure of AD cells to vinorelbine resulted in
concentration- and time-dependent increases in the protein levels
of both p53 and p21. The amount of p53 protein increased
approximately 23% 3h after the exposure of AD cells to 0.1 mM of
vinorelbine (Figure 2, left panel). The maximal induction (over
two-fold) of the protein by 0.05mM of vinorelbine was achieved at
24h (Figure 3, middle panel). The increase of p21 protein
paralleled the elevated protein level of p53, indicating that the
p21 induction by vinorelbine is a p53-dependent process in AD
cells.
Consistent with our previous observation (Gao et al, 1999) no
p21 protein was detected in untreated AI cells, as shown in
Figure 2, right panel. However, the p21 protein became detectable
7h after exposure of the AI cells to vinorelbine. In contrast to AD
cells, constant high levels of p53 proteins were observed in AI cells
that did not respond to vinorelbine.
Treatment of AD cells with various concentrations of paclitaxel
also significantly induced p53 expression and resulted in a
concentration-dependent increase in the level of p21 protein
(Figure 3, left panel). However, no significant changes in
expression of those proteins were observed in AI cells under the
same experimental conditions (data not shown).
Analysis of cell cycle distribution showed higher percentage of
cells (21.09%) at Gl phase when AI cells were exposed to
vinorelbine compared to cells exposed to paclitaxel (13.81%,
Figure 4), probably due to the expression of p21 induced by
vinorelbine in this cell line.
To examine whether vinorelbine stimulates p21 expression
through its promoter transcriptional activation, a p21 luciferase
reporter construct containing the full-length of human p21
promoter was transiently transfected into both AD and AI cells.
At 1 day after the transfection, the cells were either exposed for
24h to different concentrations of vinorelbine, or vehicle as
controls. As shown in Figure 5, the luciferase activity was
significantly induced by vinorelbine (Po0.01) in both AD (panel
A) and AI (panel B) cells. Maximal induction in AD cells was
achieved at concentration of 0.05mM with approximately 14-fold
increase of the luciferase activity (Po0.01). Higher concentration
(0.1mM) of the treatment reduced the extent of the induction,
possibly due to cytotoxicity (Figure 5, panel A). Induction of
reporter activity in AI cells occurred at concentration of 0.05mM,
and achieved maximal induction at concentration of 0.10mM,
almost a nine-fold increase (Po0.01). In contrast to vinorelbine,
paciltaxel did not stimulate the p21 reporter activity in AI cells
under the same experimental conditions (panel C). These findings
paralleled the results obtained by Western blotting assay.
Vinorelbine-mediated p21 induction in AI cells through
p53 and Spl pathways
To define the role p53 played in the vinorelbine-mediated
upregulation of p21 expression, we compared the stimulation
effects of vinorelbine on the full p21 promoter reporter and the
reporter without p53 regulatory binding sites (pWPdel-BstXI). As
shown in Figure 6, the basal level of the transcriptional activity of
the full promoter of p21 reporter gene in AD cells was found to be
four-fold higher than that of pWPdel-BstXI (Po0.01). In AI cells,
the basal activity of pWPdel-BstXI was 1.5-fold higher than that of
F-p21. Although a substantial increase in F-p21 activity (approxi-
mately 14-fold) was observed when the AD cells were exposed to
0.05mM of vinorelbine, no such induction for pWPdel-BstXI
activity was obtained in AD cells under the same experimental
condition (Figure 6, panel A).
In contrast to AD cells, as shown in Figure 6, panel B, both
reporter genes in AI cells were similarly and significantly stimulated
by vinorelbine in a concentration-dependent manner, although the
extent of the induction of those reporter activities by vinorelbine is
different in AI cells. The maximal induction of F-p21 reporter
activity (nine-fold) was achieved at concentration of 0.10mM of
vinorelbine (Po0.01), whereas only a 4.5-fold increase of pWPdel-
BstXI activity was obtained under the same experimental conditions.
Recent data have indicated that p21 expression can be induced
by histone deacetylase inhibitors through p53-independent Spl
sites of the promoter of the gene (Sowa et al, 1997). To evaluate
whether vinorelbine-mediated induction of p21 in AI cells followed
a similar mechanism analogous to histone deacetylase inhibitors,
transfection assays were carried out using p21 reporter plasmids
containing different lengths of Spl sites, or their mutated forms. As
Figure 2 Time-dependent induction of p53 and p21
WAFI/CIP1 expression
in androgen-dependent (AD) and- independent (AI) prostate cancer cell
lines by vinorelbine. Androgen-independent and AI cells grown exponen-
tially were exposed to 0.1mM of vinorelbine for indicated periods of time.
The cells were harvested, washed, and total proteins extracted. Proteins
(50mg) were subjected to 4/10% stacking SDS–PAGE, electrotransferred
to nitrocellulose membrane, and immunoblotted with p21
WAFI/CIP1 and
p53 monoclonal antibodies, respectively. The same membrane was
stripped, and reprobed with antibody against b-actin for equal loading
control.
Figure 3 Effects of paclitaxel (left panel) and vinorelbine (middle and
right panel) on the expression of p53 and p21
WAFI/CIPI in androgen-
dependent (AD, left and middle panel) and-independent (AI, right panel)
prostate cancer cell lines. AD and AI cells grown exponentially were
exposed for 24h to different concentrations of paclitaxel (left panel) or
vinorelbine (middle and right). The cells were harvested, washed, and total
proteins extracted. Fifty mg of proteins were subjected to 4%/10% stacking
SDS-PAGE, electrotransferred to nitrocellulose membrane, and immuno-
blotted with p21
WAFI/CIPI and p53 monoclonal antibodies, respectively. The
same membrane was stripped and reprobed using antibody against b-actin
for equal loading control.
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sshown in Figure 7, p21 reporter with the complete promoter
showed highest inducible activity (over nine-fold increase) by
vinorelbine. In contrast, approximately a 4.5-fold increase of
luciferase activity induced by vinorelbine was obtained when the
reporter contained only complete Spl sites (pWPdel-BstXI).
Similar transcriptional activation was obtained using pWPlOl in
which Spl-1 and Spl-2 were deleted, indicating that those two Spl
sites were not essential for vinorelbine-mediated p21 activation. Of
note, under the same experimental conditions only approximately
a two-fold increase (Po0.05) of the activity was observed in
pWPdel-SmaI reporter containing only Spl-5 and Spl-6. Moreover,
if the reporter contained just three tandem repeats of consensus
Spl sites (Spl-p21), no significant induction of p21 activity by
0.1mM of vinorelbine (1.74-fold, P40.05) was observed, while a
significant increase was achieved by 0.1mM of TSA, a well-
established histone deacetylase inhibitor.
Synergistic combination of paclitaxel and vinorelbine
It has been reported that flavopridol, an inhibitor of cyclin-
dependent kinases, significantly enhances paclitaxel-induced
apoptosis when paclitaxel precedes flavopridol (Schwartz et al,
2002). Since vinorelbine, but not paclitaxel, was able to induce p21
expression in AI cells, we postulated that the sequential exposure
of AD and AI cells to paclitaxel followed by vinorelbine might
produce synergistic outcomes. To explore this possibility, we
treated the cells with either paclitaxel or vinorelbine alone for 7
days, or paclitaxel for 3 days followed by paclitaxel plus
vinorelbine for additional 4 days, and analysed for the outcomes
of the sequential combination by a PC program CalcuSyn (Kreis
et al, 1997). As expected, this combination resulted in a significant
synergy in both AD and AI cells (Figure 8). All combination
indexes were smaller than 1 (Figure 8, panels B and D). However,
on concurrent exposure of AI cells to paclitaxel plus vinorelbine,
the calculated combination indexes were found to be between 1.5
and 3.8, suggesting an antagonistic to moderate additive effects
(data not shown). The calculated IC50 under the described
experimental conditions were shown in Table 1 in which the IC50
from the combination were significantly smaller than with either
paclitaxel or vinorelbine alone (Po0.001) in both AD and AI cells.
In addition, while the sensitivity of AD cells to paclitaxel (IC50
0.035nM) was almost 10-fold higher than that of vinorelbine
(0.31nM, Po0.001), no significant difference was observed in AI
cells (0.65nM of paclitaxel vs 0.59nM of vinorelbine, P40.05).
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Figure 4 Cell cycle distribution of AI cells after exposure to paclitaxel or vinorelbine. Androgen-independent cells at exponential growth phase were
exposed to 0.05mM of paciltaxel (middle panel) or vinorelbine (right panel) for 24h. The cells were harvested, washed with cold PBS, fixed with 70% ethanol
and propidium iodide (PI) stained. The cell cycle distribution was then analysed by FACScan (Beckton Dickinson, Mountainview, CA, USA).
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Figure 5 Effect of vinorelbine (NVB) or paclitaxel (TAX) on p21 transactivation in AD or AI cells. Androgen-dependent or AI cells grown at exponential
phase were cotransfected in serum-free RPMI-1640 medium with 1mg cDNA of full promoter-p21 reporter and 1mg cDNA of pSV-b-galactosidase using
Effectene according to manufacturer’s instructions. At 1 day after the transfection, the cells were exposed for 24h to concentrations of NVB or TAX, as
indicated. The cells were washed, and lysed for luciferase activity assay as described in Materials and Methods. The luciferase activities in AD or AI cells were
normalised to the activity of b-galactosidase for the equal efficiency of the transfections. The data are expressed as means7s.d. from three separate
experiments.
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sDISCUSSION
Using a series deletion of p21 reporter constructs, we have
demonstrated that vinorelbine induced p21 expression in AI cells
in both p53-dependent and -independent manners. While nine-
fold induction of activity of full promoter-p21 reporter was
achieved at concentration of 0.10mM of vinorelbine (Po0.01), only
a 4.5-fold increase in activity of pWPdel-Bst XI reporter (only
contains six Spl binding sites) was obtained under the same
experimental conditions. Deletion of Spl-1 and Spl-2 from
pWPdel-Bst XI to generate pWPlOl did not result in further
reduction of the transcriptional activation (4.5-fold), suggesting
that Spl-1 and Spl-2 within the p21 promoter was not essential for
vinorelbine-mediated p21 activation. This effect is distinct from
the effects of phorbol ester and of okadaic acid (Biggs et al, 1996).
However, using the reporter pWPdel-Sma that contains Spl-5 and
Spl-6, the expression only achieved approximately a two-fold
induction (Po0.01). Moreover, activity of three tandem repeats of
consensus Spl-driven reporter (Spl-luc) was only induced 1.7-fold
by vinorelbine, whereas it was induced over 30-fold by TSA, which
was consistent with previous report (Sowa et al, 1997). These
findings indicate that in addition to two p53 regulatory sites, Spl-3
and Spl-4 in the promoter of human p21 gene are required
for vinorelbine-mediated transcriptional activation of p21 in the
p21-deficient AI cells, and this induction is distinct from that seen
with histone deacetylase inhibitors.
Our study also demonstrated that vinorelbine failed to induce
transcriptional activation of p21 reporters without p53 binding
sites in AD cells. One possible interpretation of this result may be
that in the presence of active p53, vinorelbine-mediated p21
induction is preferentially achieved through a p53-dependent
pathway as indicated by significant increase in the levels of p53
proteins (Figure 1), and the Spl pathway is activated when p53
activity is not present. The p53 proteins in AI cells were constantly
maintained at a high level and no changes were observed in
response to the treatment with vinorelbine (Figures 2 and 3),
suggesting an abnormality present in the product of this tumour
suppressor gene.
Paclitaxel has been reported to induce concentration- and time-
dependent accumulation of p21 in both p53 wild-type MCF-7 and
p53-null PC3M cells (Blagosklonny et al, 1995; Barboule et al,
1997). In this study, we demonstrated that paclitaxel failed to
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Figure 6 Role of p53 binding sites within the promoter of p21 gene
played in the vinorelbine-mediated p21 activation in AD and AI cells.
Androgen-dependent and AI cells grown at exponential phase were
cotransfected in serum-free RPMI-1640 medium with 1mg cDNA of full
promoter-p21 reporter or pWPdel-BstXI and 1mg cDNA of pSV-b-
galactosidase using Effectene according to the manufacturer’s instructions.
At 1 day after the transfection, the cells were exposed for 24h to
concentrations of vinorelbine as indicated. The cells were washed and lysed
for luciferase activity assay as described in Materials and Methods. The
luciferase activities in AD and AI cells were normalised to the activity of b-
galactosidase for the equal efficiency of the transfections. The data are
expressed as means7 s.d. from three separate experiments.
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G: Schematic representation of p21 reporters
Figure 7 Involvement of Spl-3 and Spl-4 within the promoter of p21
gene in the vinorelbine-mediated p21 transcriptional activation in
androgen-independent prostate cancer cells. Androgen-independent cells
grown at exponential phase were cotransfected in serum-free RPMI-1640
medium with 1mg cDNA of full promoter p21 reporter, pWPdel-BstXI,
pWPlOl, pWPdel-Sma I, Spl-p21, or mtSpl-p21 and 1mg cDNA of pSV-b-
galactosidase using Effectene according to the manufacturer’s instructions.
At 1 day after the transfection, the cells were exposed for 24h to different
concentrations of vinorelbine, as indicated. The cells were washed, and
lysed for luciferase activity assay as described in Materials and Methods. The
luciferase activities in AD and AI cells were normalised to the activity of b-
galactosidase for the equal efficiency of the transfections. The data are
expressed as means7s.d. from three separate experiments.
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been reported in that paclitaxel could not induce p21 expression in
NIH-OVCAR-3 cells that are deficient in basal expression of p21.
Therefore, these data indicate that paclitaxel may be unable to
induce p21 expression in cells that are deficient in basal expression
of the gene. The obvious consequence is that such cells may be
resistant to apoptotic induction by paclitaxel, which was supported
by this study in that the sensitivities of AD and AI in response to
paclitaxel were significantly different from that to vinorelbine. This
conclusion is also supported by the fact that increased p21 level
usually parallels induction of apoptosis mediated by chemother-
apeutic agents, including taxanes (Ali et al, 2003; Ganansia-
Leymarie et al, 2003; Lee et al, 2003). Paclitaxel was able to induce
p21 expression in AD cell, thus producing greater cytoxicity (IC50
0.035nM in AD as compared 0.61nM in AI cells). In contrast,
vinorelbine was able to induce p21 expression in both AD and AI
cells, hence, only a small difference in the sensitivity was observed
between those cell lines (IC50 in AD 0.31 vs 0.59nM in AI cells).
Alterations in expression of cell cycle regulators, such as E2F-1,
cyclin/Cdks (cyclin Dl/Cdk4, cyclin A/Cdk2), and cyclin-dependent
kinase (Cdk) inhibitors (p6, p21, and p27), play an important role
in regulation of drug sensitivity (Hochhauser et al, 1996; St Croix
et al, 1996; Li et al, 1997). NIH-OVCAR-3 cells that are deficient
both in basal- and paclitaxel-induced p21 are associated with
apoptotic resistance (Barboule et al, 1997). We have previously
demonstrated that loss of p21 expression in our newly established
AI cells may play an important role in apoptotic resistance (Gao
et al, 1999). Therefore, restoration of normal expression of those
cell cycle modulators may allow cells to regain apoptotic
sensitivity. We recently demonstrated that AI cells exposed to
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Figure 8 Synergistic effects of sequential combination of paclitaxel and vinorelbine in AD and AI cells. Androgen-dependent and AI cells at exponential
growth phase in 96-well dishes were exposed to a series dilution of either paclitaxel (TAX) or vinorelbine (NBV) alone for 7 days or paclitaxel for 3 days
followed by paclitaxel plus vinorelbine for additional 4 days. Cell growth was determined by MTT, and the combination indexes (CI) were calculated by aP C
program CalcuSyn as described in the Materials and Methods. Panels A and B, the effect–concentration plots in AD (A) and AI (B); Panels C and D, the
effect –combination index plots in AD (C) and AI (D). Panel E: the expression of p53 and p21 in AD and AI cells after exposure for 24h to NVB or TAX
alone or NVB plus TAX.
Table 1 IC50 in AD and AI cells in response to the treatment of either paclitaxel or vinorelbine alone for 7 days, or paclitaxel for 3 days followed by
vinorelbine for additional 4 days
Cell lines Treatment IC50 (nM) P-value
AD Paclitaxel (T) 0.03570.005 Tvs N, Po0.01
AD NVB (N) 0.31070.061 T vs T+N, Po0.001
AD Paclitaxel followed by T + N 0.001570.0007 N vs T+N, Po0.001
AI Paclitaxel (T) 0.65070.140 T vs N, P40.05
AI NVB (N) 0.59070.091 T vs T+N, Po0.001
AI Paclitaxel followed by T + N 0.11070.003 N vs T+N, Po0.001
The IC50 was calculated and statistically analysed between the treatments using PC program Sigma Plot from three separate experiments. T¼treated with paclitaxel, N¼treated
with vinorelbine (NVB), and T+N¼treated with paclitaxel followed by paclitaxel plus NVB as described in ‘Materials and Methods’.
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probably due to transcriptional activation of p21 by TSA (Sowa
et al, 1997; Wang et al, 2001). In this report, we demonstrated that
vinorelbine, but not paclitaxel, was able to restore p21 expression
of AI cells. Our findings, thus, may provide a theoretical basis for
the synergistic combination of vinorelbine and paclitaxel for the
treatment of advanced prostate cancer. The significant synergistic
effects produced by sequential exposures of both AD and AI cells
to paclitaxel followed by paclitaxel plus vinorelbine supported this
hypothesis.
Expression of p21 has been demonstrated to be regulated
through both p53-dependent and-independent pathways (Cartel
and Tyner, 1999). Transcriptional activation of p21 triggered by
DNA damage was found to be present in a p53-dependent manner
in most tissues/cells acting by two p53- binding sites located in
promoters -2301 and -394 of p21 gene. p21 expression induced by
other factors, that is, Zta, NDF, c-Rel, or ribonucleotide inhibitors,
such as pyrazofurin or cyclopentenylcytosine, have also been
indicated to be dependent on a p53 pathway associated with
activation or stabilisation of p53 RNA or protein (Linke et al, 1996;
Gartel and Tyner, 1999).
Regulatory sites of STAT family transcription factors, the steroid
nuclear receptor family including androgen receptor and vitamin
D receptor, are also found within the promoters of the human p21
gene (Gartel and Tyner, 1999; Lu et al, 2000). The promoter
between  119 and the start site of the transcription of the human
p21 gene contains six Spl regulatory sites (termed as Spl-1 to Spl-6)
and appears functionally different. Several important biological
modifiers have been shown to activate p21 transcription through
different Spl binding sites (Cartel and Tyner, 1999). For example,
phorbol ester and okadaic acid induce p21 expression through
Spl-1 and Spl-2 sites (Biggs et al, 1996), whereas the Spl-3 site in
the promoter of p21 has been shown to be required for p21
induction by transforming growth factor-b, histone deacetylase
inhibitors such as TSA and butyrate, lovastatin, nerve growth
factor (NGF) as well as calcium (Datto et al, 1995; Nakano et al,
1997; Prowse et al, 1997; Sowa et al, 1997; Lee et al, 1998; Billon
et al, 1999). In this report, we demonstrated that Spl-3 and Spl-4 in
the promoter of human p21 gene are required for vinorelbine-
mediated transcriptional restoration of p21 in the p21-deficient Al
cells, which may provide a new mechanism in drug-mediated p21
regulation.
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